Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Eva Drazanova"'
Autor:
Iveta Harastova-Pavlova, Eva Drazanova, Lucie Kratka, Petra Amchova, Maria Hrickova, Ondrej Macicek, Jiri Vitous, Radovan Jirik, Jana Ruda-Kucerova
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 181, Iss , Pp 117656- (2024)
Background: Major depressive disorder (MDD) is a mental illness with a high worldwide prevalence and suboptimal pharmacological treatment, which necessitates the development of novel, more efficacious MDD medication. Nuclear magnetic resonance (NMR)
Externí odkaz:
https://doaj.org/article/85ee4d08964d423eb85aabdcd0d44f41
Autor:
Katerina Horska, Jan Kucera, Eva Drazanova, Gabriela Kuzminova, Petra Amchova, Maria Hrickova, Jana Ruda-Kucerova, Silje Skrede
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 176, Iss , Pp 116763- (2024)
Background: Antipsychotics are indispensable in the treatment of severe mental illneses, however adverse metabolic effects including diabetes, weight gain, dyslipidemia, and related cardiovascular morbidity are common, and current pharmacological str
Externí odkaz:
https://doaj.org/article/317d5309e5a84e589e27043d4e5ff927
Autor:
Iveta Pavlova, Eva Drazanova, Lucie Kratka, Petra Amchova, Ondrej Macicek, Jana Starcukova, Zenon Starcuk, Jana Ruda-Kucerova
Publikováno v:
The World Journal of Biological Psychiatry. 24:414-428
Publikováno v:
Neurodegenerative Diseases Biomarkers ISBN: 9781071617113
Neurodegenerative Diseases Biomarkers
Neurodegenerative Diseases Biomarkers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26151286a7255d3a9e8f8b1531021078
https://doi.org/10.1007/978-1-0716-1712-0_18
https://doi.org/10.1007/978-1-0716-1712-0_18
Autor:
Hana Kotolová, Zenon Starčuk, Katerina Horska, Zuzana Babinská, Eva Drazanova, Nadezda Vaskovicova, Radim Skoupy, Jana Ruda-Kucerova, Marcela Buchtová, Lucie Vrlíková, Lucie Krátká
Publikováno v:
Pharmacological Reports. 71:839-847
Background Olanzapine is a frequently used atypical antipsychotic drug known to exert structural brain alterations in animals. This study investigated whether chronic olanzapine exposure alters regional blood brain perfusion assessed by Arterial Spin
Autor:
Zenon Starčuk, Jana Ruda-Kucerova, Alzbeta Sejnoha Minsterova, Eva Drazanova, Anas Arab, Nikoletta Szabó, Amit Khairnar, Irena Rektorová
Publikováno v:
Neurotoxicity Research. 36:724-735
Methamphetamine (METH) abuse is known to increase the risk of Parkinson's disease (PD) due to its dopaminergic neurotoxicity. This is the rationale for the METH model of PD developed by toxic METH dosing (10 mg/kg four times every 2 h) which features
Autor:
Irena Rektorová, Jana Ruda-Kucerova, Alexandra Chovsepian, Qi Shang, Zenon Starčuk, Eva Drazanova, Anas Arab, Constantinos Hadjistyllis, Nikoletta Szabó, Alzbeta Sejnoha Minsterova, Amit Khairnar, Francisco Pan-Montojo
Publikováno v:
Journal of neurochemistryREFERENCES. 158(3)
Clinical diagnosis of Parkinson's disease (PD) occurs typically when a substantial proportion of dopaminergic neurons in the substantia nigra (SN) already died, and the first motor symptoms appear. Therefore, tools enabling the early diagnosis of PD
Autor:
Claudio Bucolo, Alexandra Šulcová, Martina Di Bartolomeo, Julia Fedotova, Tibor Štark, Lucie Krátká, Fabiana Piscitelli, Carsten T. Wotjak, Raphael Mechoulam, Vincenzo Micale, Claudio D'Addario, Chiara Bianca Maria Platania, Jana Ruda-Kucerova, Zenon Starčuk, Fabio Arturo Iannotti, Salvatore Salomone, Eva Drazanova, Vladimir Pekarik, Filippo Drago, Zuzana Babinská, Vincenzo Di Marzo, Giovanni Giurdanella, Roberta Di Marco
Publikováno v:
Biochemical pharmacology. 177
Gestational methylazoxymethanol acetate (MAM) treatment produces offspring with adult phenotype relevant to schizophrenia, including positive- and negative-like symptoms, cognitive deficits, dopaminergic dysfunction, structural and functional abnorma
Autor:
Regina Demlová, Katerina Horska, Michal Karpisek, Tomáš Kašpárek, Eva Drazanova, Hana Kotolová, Jana Ruda-Kucerova
Publikováno v:
Neuropharmacology. 123:148-158
Schizophrenia appears to be linked to higher incidence of metabolic syndrome even in the absence of antipsychotic treatment. Atypical antipsychotics substantially differ in their propensity to induce metabolic alterations. Aripiprazole is considered
Autor:
Tibor Štark, Michal Maryška, Eva Drazanova, Filippo Drago, Martin Kuchar, Jana Ruda-Kucerova, Vincenzo Micale, Zenon Starčuk, Lucie Krátká
Publikováno v:
Scientific Reports. 2019, vol. 9, issue 1, p. 1-10.
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-10 (2019)
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-10 (2019)
Clinical studies consistently report structural impairments (i.e.: ventricular enlargement, decreased volume of anterior cingulate cortex or hippocampus) and functional abnormalities including changes in regional cerebral blood flow in individuals su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9a971e7d05561d4cd4e6d84f0550dab
https://hdl.handle.net/11012/202970
https://hdl.handle.net/11012/202970